  |
 | Up a level |
Shah, M.A. and Udrea, A.A. and Bondarenko, I. and Mansoor, W. and Sánchez, R.G. and Sarosiek, T. and Bozzarelli, S. and Schenker, M. and Gomez-Martin, C. and Morgan, C. and Özgüroglu, M. and Pikiel, J. and Kalofonos, H.P. and Wojcik, E. and Buchler, T. and Swinson, D. and Cicin, I. and Joseph, M. and Vynnychenko, I. and Luft, A.V. and Enzinger, P.C. and Salek, T. and Papandreou, C. and Tournigand, C. and Maiello, E. and Wei, R. and Ferry, D. and Gao, L. and Oliveira, J.M. and Ajani, J.A. (2022) Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers, Vol.14 (iss. 5). p. 1168. ISSN 2072-6694
Rugo, H.S. and Pennella, E.J. and Gopalakrishnan, U. and Hernandez-Bronchud, M. and Herson, J. and Koch, H.F. and Loganathan, S. and Deodhar, S. and Marwah, A. and Manikhas, A. and Bondarenko, I. and Parra, J.D. and Abesamis-Tiambeng, M.L.T. and Akewanlop, C. and Vynnychenko, I. and Sriuranpong, V. and Roy, S. and Yanez Ruiz, E.P. and Barve, A. and Waller, C.F. (2021) Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial. The Breast, 58. pp. 18-26. ISSN 0960-9776
Bedke, Jens and Rini, Brian I. and Plimack, Elizabeth R. and Stus, V. and Gafanov, Rustem and Waddell, Tom and Nosov, D. and Pouliot, Frédéric and Soulières, D. and Melichar, B. and Vynnychenko, I. and Azevedo, Sergio Jobim and Borchiellini, Delphine and McDermott, Raymond S. and Tamada, Satoshi and Nguyen, Allison Martin and Wang, S. (2021) Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. EUROPEAN UROLOGY, 82 (4). pp. 427-439. ISSN ISSN : 0302-2838
Gafanov, R. and Powles, T.B. and Bedke, J. and Stus, V. and Wadde, T.S. and Nosov, D. and Pouliot, F. and Soulières, D. and Melichar, B. and Azevedo, S. and McDermott, R.S. and Vynnychenko, I. and Borchiellini, D. and Markus, M. and Bondarenko, I. and Lin, J. and Burgents, J. and Molife, L. R. and Rini (2021) Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study. Annals of Oncology, 32 (5). p. 694. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
Rini, B.I. and Plimack, E.R. and Stus, V. and Gafanov, R. and Hawkins, R. and Nosov, D. and Pouliot, F. and Alekseev, B. and Soulières, D. and Melichar, B. and Vynnychenko, I. and Kryzhanivska, A. and Bondarenko, I. and Azevedo, S.J. and Borchiellini, D. and Szczylik, C. and Markus, M. and McDermott, R.S. and Bedke, J. and Tartas, S. and Chang, Y.-H. and Tamada, S. and Shou, Q. and Perini, R.F. and Chen, M. and Atkins, M.B. and Powles, T. (2019) Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England Journal of Medicine = N Engl J Med, 380. pp. 1116-1127. ISSN 0028-4793 (print); 1533-4406 (online)
Lordick, F. and Schuler, M. and Al-Batran, S-E. and Zvirbule, Z. and Manikhas, G. and Rusyn, A. and Vinnyk, Y. and Vynnychenko, I. and Fadeeva, N. and Nechaeva, M. and Dudov, A. and Gotovkin, E. and Pecheniy, A. and Bazin, I. and Bondarenko, I. and Melichar, B. and Huber, C. and Sahin, U. and Türeci, Ö. (2016) Claudin 18.2 – a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer. Annals of Oncology, 27 (supp_9). mdw582.001. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
Schuler, M. and Al-Batran, S.-E. and Zvirbule, Z. and Manikhas, G. and Lordick, F. and Rusyn, A. and Vinnyk, Y. and Vynnychenko, I. and Fadeeva, N. and Nechaeva, M. and Dudov, A. and Gotovkin, E. and Pecheniy, A. and Bazin, I. and Bondarenko, I. and Melichar, B. and Huber, C. and Türeci, Ö. and Sahin, U. (2016) Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. Annals of Oncology, Vol.27 (supp_6). P.- LBA45. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
